• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Covid-19: India is at centre of global vaccine manufacturing, but opacity threatens public trust.

作者信息

Thiagarajan Kamala

机构信息

Tamil Nadu, India.

出版信息

BMJ. 2021 Jan 28;372:n196. doi: 10.1136/bmj.n196.

DOI:10.1136/bmj.n196
PMID:33509837
Abstract
摘要

相似文献

1
Covid-19: India is at centre of global vaccine manufacturing, but opacity threatens public trust.新冠疫情：印度是全球疫苗生产的中心，但透明度问题正威胁公众信任。
BMJ. 2021 Jan 28;372:n196. doi: 10.1136/bmj.n196.
2
COVID-19 Infodemic and Public Trust from the Perspective of Public and Global Mental Health.从公众和全球心理健康的角度来看 COVID-19 信息疫情与公众信任
Psychiatr Danub. 2020 Autumn-Winter;32(3-4):449-457. doi: 10.24869/psyd.2020.449.
3
Protecting Indian health workforce during the COVID-19 pandemic.在新冠疫情期间保护印度卫生人力
J Family Med Prim Care. 2020 Sep 30;9(9):4541-4546. doi: 10.4103/jfmpc.jfmpc_925_20. eCollection 2020 Sep.
4
Public trust in vaccination: an analytical framework.公众对疫苗接种的信任：一个分析框架。
Indian J Med Ethics. 2017 Apr-Jun;2(2):98-104. doi: 10.20529/ijme.2017.024.
5
Covid-19: Vaccine trials need more transparency to enable scrutiny and earn public trust, say experts.专家表示，新冠疫情：疫苗试验需要更高的透明度，以便接受审查并赢得公众信任。
BMJ. 2020 Oct 22;371:m4042. doi: 10.1136/bmj.m4042.
6
Protective Behavior against COVID-19 among the Public in Kuwait: An Examination of the Protection Motivation Theory, Trust in Government, and Sociodemographic Factors.科威特公众对 COVID-19 的防护行为：保护动机理论、对政府的信任和社会人口因素的考察。
Soc Work Public Health. 2020 Sep 1;35(7):546-556. doi: 10.1080/19371918.2020.1806171.
7
Kerala's response to COVID-19.喀拉拉邦对 COVID-19 的应对措施。
Indian J Public Health. 2020 Jun;64(Supplement):S99-S101. doi: 10.4103/ijph.IJPH_459_20.
8
Public vaccine manufacturing capacity in the Latin American and Caribbean region: current status and perspectives.拉丁美洲和加勒比地区的公共疫苗生产能力：现状与展望
Biologicals. 2012 Jan;40(1):3-14. doi: 10.1016/j.biologicals.2011.09.013. Epub 2011 Oct 26.
9
Clinical and epidemiological profile of patients infected by COVID-19 at a tertiary care centre in North India.印度北部一家三级医疗中心新冠病毒感染患者的临床和流行病学概况。
Monaldi Arch Chest Dis. 2020 Nov 27;90(4). doi: 10.4081/monaldi.2020.1357.
10
The trouble with trust: Time-series analysis of social capital, income inequality, and COVID-19 deaths in 84 countries.信任的问题：84 个国家的社会资本、收入不平等与 COVID-19 死亡人数的时间序列分析。
Soc Sci Med. 2020 Oct;263:113365. doi: 10.1016/j.socscimed.2020.113365. Epub 2020 Sep 16.

引用本文的文献

1
COVID-19 critical success factors in Indian healthcare industry-A DEMATEL approach.印度医疗行业中COVID-19的关键成功因素——一种决策试验与评价实验室方法
J Multi Criteria Decis Anal. 2022 Jan-Apr;29(1-2):135-149. doi: 10.1002/mcda.1763. Epub 2021 Aug 5.
2
A comparative analysis of supply chain factors impacting COVID-19 vaccine security in high-income countries (HICs) and low-income and middle-income countries (LMICs).高收入国家（HICs）和中低收入国家（LMICs）中影响 COVID-19 疫苗安全的供应链因素的比较分析。
BMJ Glob Health. 2024 Nov 8;9(11):e015136. doi: 10.1136/bmjgh-2024-015136.
3
Estimation of SARS-CoV-2 IgG Antibodies in Healthcare Worker-Administered Covishield and Covaxin Vaccines at a Tertiary Care Hospital in Jharkhand, India.
印度贾坎德邦一家三级护理医院对医护人员接种的Covishield和Covaxin疫苗中SARS-CoV-2 IgG抗体的评估。
Cureus. 2023 Oct 24;15(10):e47566. doi: 10.7759/cureus.47566. eCollection 2023 Oct.
4
The status of COVID-19 vaccines in India: A review.印度新冠疫苗的现状：综述
Vacunas. 2023 Apr 25. doi: 10.1016/j.vacun.2023.04.003.
5
Impact of COVID-19 vaccines on the health status of young female adults from India: A cross-sectional study.新冠疫苗对印度年轻成年女性健康状况的影响：一项横断面研究。
J Family Med Prim Care. 2023 Feb;12(2):338-351. doi: 10.4103/jfmpc.jfmpc_1574_22. Epub 2023 Feb 28.
6
Co-infection associated with SARS-CoV-2 and their management.与严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）相关的合并感染及其管理。
Future Sci OA. 2023 Feb 3;8(9):FSO819. doi: 10.2144/fsoa-2022-0011. eCollection 2022 Oct.
7
Perception of Availability, Accessibility, and Affordability of COVID-19 Vaccines and Hesitancy: A Cross-Sectional Study in India.对2019冠状病毒病疫苗可及性、可获取性、可负担性的认知及犹豫态度：印度的一项横断面研究
Vaccines (Basel). 2022 Nov 25;10(12):2009. doi: 10.3390/vaccines10122009.
8
An efficacy and safety report based on randomized controlled single-blinded multi-centre clinical trial of ZingiVir-H, a novel herbo-mineral formulation designed as an add-on therapy in adult patients with mild to moderate COVID-19.基于随机对照、单盲、多中心临床试验的 ZingiVir-H 疗效和安全性报告，ZingiVir-H 是一种新型的草药-矿物配方，设计用于治疗轻度至中度 COVID-19 的成年患者的附加疗法。
PLoS One. 2022 Dec 6;17(12):e0276773. doi: 10.1371/journal.pone.0276773. eCollection 2022.
9
The Vaccine World of COVID-19: India's Contribution.新冠疫情下的疫苗世界：印度的贡献
Vaccines (Basel). 2022 Nov 17;10(11):1943. doi: 10.3390/vaccines10111943.
10
Addressing Different Needs: The Challenges Faced by India as the Largest Vaccine Manufacturer While Conducting the World's Biggest COVID-19 Vaccination Campaign.满足不同需求：印度作为最大疫苗生产国在开展全球最大规模新冠疫苗接种运动时所面临的挑战。
Epidemiologia (Basel). 2021 Sep 17;2(3):454-470. doi: 10.3390/epidemiologia2030032.